Filed by newsfilecorp.com For Immediate Release Orgenesis Appoints Itamar Raz as Newest Member of Board of Advisors GERMANTOWN, MD

Orgenesis Appoints Itamar Raz as Newest Member of Board of

GERMANTOWN, MD Mar. 16, 2015 Orgenesis

Inc. (OTCQB: ORGS) a development-stage company with a novel therapeutic

technology dedicated to converting a patient's own liver cells into functioning

insulin-producing cells as a treatment for diabetes, today announced that

Professor Itamar Raz has been appointed to the Orgenesis board of advisors.

Prof. Raz has been involved in a number of organizations

focused on diabetes, as well as in other medical associations. In 2004, he

became the head of the Israel National Diabetes Council. At this time he also

became President of the nonprofit organization, D-Cure (Diabetes Care to Cure in

Israel). Prof. Raz is well known as both an academic and clinician, having

served as Chief Physician at Hebrew University and Director of the Hadassah

Center for the Prevention of Diabetes and its Complications at Hadassah

University Hospital.

Itamar Raz is a choice addition to our board of advisors at

Orgenesis, said Vered Caplan, Chairperson and CEO of Orgenesis. He has spent

time in academic medicine, which has given way to a thorough knowledge in the

medical field and in hospitals. His experience on both national and

international associations, particularly those centering on diabetes, will make

his transition to the board seamless. He will be an incredible asset in our

quest to solve diabetes with regenerative medicine.

Professor Itamar Raz is a preeminent authority in the diabetes

world, said Dr. Alexander Fleming, Orgenesis advisory board member and former

head of diabetes drug review at the FDA. He brings great experience in clinical

trials and therapeutic development across the spectrum of drugs, biologics, and

devices in type 1 and type 2 diabetes. He is a highly respected scientist and

clinician across the globe for his many contributions and insights. I am

thrilled that Prof. Raz has decided to join us.

Prof. Raz served from 1966 to 1969 as a Captain in the

Military; he was also involved in Infantry and the Medical Corps. He studied

Pharmacology at Hebrew University, and received his B.S. at the Hadassah School

of Pharmacy in Jerusalem. He then obtained his M.D. in medicine and internal

medicine in his following studies, which took place at the Hadassah University

Currently, Itamar Raz is a Professor of Medicine and Head of

the Diabetes Unit at the Hadassah Ein Kerem Hospital in Jerusalem.

About Orgenesis, Inc.

Orgenesis is a development

stage company that is committed to curing Type 1 Diabetes. In pursuit of this

goal, the Company is developing a novel technology that combines cellular

therapy and regenerative medicine. Through a proprietary biologic process called

cellular trans-differentiation, Orgenesis has proven that, when exposed ex

vivo to certain pancreatic transcription factors and in specific sequence, human

adult liver cells can be transformed into fully functional, beta cell-like

insulin producing cells (IPCs). After ex vivo expansion, the IPCs are re-infused

via the portal vein. In pre-clinical models of Type 1 Diabetes (Non-Obese

Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond

to glucose challenge and successfully maintain glycemic homeostasis. In the same

NOD model, the implanted IPCs were not subject to auto-immune attack or cellular

ablation. Orgenesis plans to initiate P1/2 trials in the next 12-16 months. For

more information visit: www.orgenesis.com.

Notice Regarding Forward-Looking Statements

news release contains "forward-looking statements" which are not purely

historical. Such forward-looking statements include, among other things, the

expectations of management that our regeneration technology can be developed as

therapeutic treatment for diabetes which could, if successful, mean the end of

diabetes as we know it; that we will initiate Phase I and Phase II clinical

trials in the United States in the near-term; that we can quickly transition our

technology from research into P1 clinical trials. No assurance can be given that

any of the events anticipated by the forward-looking statements will occur or,

if they do occur, what benefits Orgenesis will obtain from them. Actual results

could differ from those projected in any forward-looking statements due to

numerous factors, including, among others, the potential failure of development

candidates to advance through preclinical studies or demonstrate safety and

efficacy in clinical testing; the ability to pass clinical trials so as to move

on to the next phase; our ability to retain key employees; our ability to

finance development and operations; our ability to satisfy the rigorous

regulatory requirements for new medical procedures; and competitors may develop

better or cheaper alternatives to our products. These forward-looking statements

are made as of the date of this news release, and we assume no obligation to

update the forward-looking statements, or to update the reasons why actual

results could differ from those projected in the forward-looking statements.

Investors should refer to the risk factors disclosure outlined in our periodic

reports filed from time-to-time with the Securities and Exchange Commission.